SUFFERN, N.Y.—CDx Diagnostics, the developer of the new EndoCDx WATS3D (wide area transepithelial sample) 3-Dimensional esophageal biopsy, announced this week that it will exhibit at the first annual Peter D. Stevens Course on Interventional Innovations in Digestive Care hosted by New York Presbyterian Hospital/Weill Cornell Medical Center. CDx Diagnostics will provide hands-on demonstrations of its new EndoCDx WATS3D biopsy with computer-assisted laboratory analysis that addresses sampling limitations of standard esophageal forceps biopsy.
The WATS3D biopsy has been shown to increase detection of Barrett's esophagus and dysplasia by up to 40 percent.1,2
The two-day course, to be held at New York-Presbyterian Hospital/Weill Cornell Medical Center on April 26 and 27, 2012, will present the latest innovations for the management of gastrointestinal diseases and cover current trends in interventional endoscopic and surgical procedures. The course is named in honor of the late Dr. Peter D. Stevens, one of the country's premier interventional endoscopists, who passed away in August 2011 after a battle with prostate cancer.
Dr. Stevens was director of endoscopy at New York-Presbyterian Hospital/Columbia University Medical Center and associate professor of clinical medicine at Columbia University College of Physicians and Surgeons.
Dr. Felice Schnoll-Sussman, assistant professor of medicine at Weill Cornell Medical College and Director of Research at The Jay Monahan Center for Gastrointestinal Health at New York-Presbyterian Hospital/Weill Cornell Medical Center and a course instructor, commented, "Esophageal cancer remains the fastest growing type of cancer in the U.S. and we welcome new technologies that will help us to reduce the incidence of this devastating disease. Studies show that WATS3D can increase detection of dysplastic cells so that we can treat the right patients earlier and improve care of our patients."
